Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology: Q3 Earnings Snapshot
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
Cardiff Oncology Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $171.000K Beat $67.857K Estimate
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow
Cardiff Oncology to Participate in September 2026 Conferences
CRDF: Second Quarter Earnings
William Blair Downgrades Cardiff Oncology to Market Perform
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate
Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
Cardiff Oncology Announces $10 Million Registered Direct Offering
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
CRDF: Phase II Update; Survival Advantage Extended
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Slideshow
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.